My only response is a question. How much of the PPS is based on this trial? I think at this point the valuation of the company needs expert analysis. Is the current drug portfolio worth $100 per share or more or less or whatever? How much of the PPS is based on potential and how much is based on sales? Questions like these are where my head is at. How does one value NBIX? Maybe today not the best day for this discussion.